ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In vitro, olverembatinib strongly inhibits the proliferation of Ba/F3 cells expressing BCR-ABL1T315I, as well as K562/Ku812 CML cells and SUP-B15 ALL cells expressing BCR-ABL1.